GlassScriptPhysician profile
Daniel J Heinmiller
NPI 1538120019
$1,512.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $240 · 2021: $361 · 2022: $375.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $371.43 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $250.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $191.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $179.66 | 2019-2022 | |
| Sanofi Pasteur INC. | $101.28 | 2019-2022 | |
| Genentech USA, INC. | $85.58 | 2020-2022 | |
| Pfizer INC. | $84.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.90 | 2019-2022 | |
| Cranial Technologies, INC | $66.34 | 2019-2022 | |
| Kaleo, INC. | $48.87 | 2020-2022 | |
| Rhodes Pharmaceuticals L.P. | $43.26 | 2019 | |
| Glaxosmithkline, LLC. | $15.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Heinmiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.